《大行报告》瑞银上调友邦(01299.HK)目标价至105元 料明年可强劲复苏
瑞银发表报告表示,重申对友邦保险(01299.HK)「买入」评级,上调对其目标价由83港元升至105港元,此按综合方式作估值,反映上调对其2021年至2024年新业务价值预测最多6%。该行上调友邦2021年及2021年每股摊薄盈利预测均3%,分别至0.6美元及0.66美元。
瑞银料友邦明年可能是强劲复苏的一年,指友邦仍是该行保险业务的首选,料公司可从新冠疫情的影响中恢复,特别是香港离岸业务;第二是友邦中国内地业务的地域扩张和产品结构多元化。
该行预测友邦於2021年新业务价值按年增长36%、料其2022年至2024年新业务价值按年增长介乎23至27%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.